

Martin Bornhäuser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5227385/publications.pdf>

Version: 2024-02-01

210
papers

11,584
citations

50276

46
h-index

31849

101
g-index

214
all docs

214
docs citations

214
times ranked

14138
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. <i>Blood</i> , 2022, 139, 87-103.	1.4	82
2	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. <i>Leukemia</i> , 2022, 36, 111-118.	7.2	31
3	Differential impact of <i>IDH1</i> mutational subclasses on outcome in adult AML: results from a large multicenter study. <i>Blood Advances</i> , 2022, 6, 1394-1405.	5.2	17
4	Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. <i>Blood Advances</i> , 2022, 6, 1941-1946.	5.2	21
5	Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2022, 108, 36-45.	0.4	2
6	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	6.4	6
7	Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML. <i>Frontiers in Oncology</i> , 2022, 12, 841608.	2.8	4
8	Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse. <i>Cancer Management and Research</i> , 2022, Volume 14, 547-559.	1.9	0
9	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. <i>BMC Cancer</i> , 2022, 22, 201.	2.6	14
10	Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML. <i>Blood Advances</i> , 2022, 6, 3294-3303.	5.2	11
11	Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. <i>Blood Advances</i> , 2022, 6, 3684-3696.	5.2	5
12	Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. <i>Journal of Hematology and Oncology</i> , 2022, 15, 60.	17.0	17
13	Predicting unplanned hospital readmission in palliative outpatients (PrePP) – study protocol of a longitudinal, prospective study to identify informal caregiver-related and structural predictors. <i>BMC Palliative Care</i> , 2022, 21, 62.	1.8	0
14	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	7.0	15
15	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	7.2	8
16	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
17	Total body irradiation + fludarabine compared to busulfan + fludarabine as reduced-toxicity conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 481-491.	2.4	10
18	Allogeneic Hematopoietic Cell Transplantation. <i>Hematologic Malignancies</i> , 2021, , 255-265.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	15
20	Displaying Lipid Chains in a Peptide-Polysaccharide-Based Self-Assembled Hydrogel Network. <i>Chemistry of Materials</i> , 2021, 33, 2756-2768.	6.7	10
21	Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 666014.	2.8	2
22	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	3.5	14
23	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. <i>Leukemia</i> , 2021, 35, 2936-2947.	7.2	15
24	Silk Hydrogel Substrate Stress Relaxation Primes Mesenchymal Stem Cell Behavior in 2D. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 30420-30433.	8.0	18
25	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. <i>Blood</i> , 2021, 137, 3145-3148.	1.4	70
26	Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 698193.	4.8	15
27	Cluster Randomized Trial: Sun Protection Intervention "Clever in Sun and Shade for Preschools" Effectiveness and Dissemination. <i>Children</i> , 2021, 8, 651.	1.5	7
28	Clonal hematopoiesis and its emerging effects on cellular therapies. <i>Leukemia</i> , 2021, 35, 2752-2758.	7.2	21
29	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2742-2748.	2.4	5
30	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	1.5	7
31	Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. <i>Cancers</i> , 2021, 13, 4785.	3.7	15
32	Reinforcement Learning for Precision Oncology. <i>Cancers</i> , 2021, 13, 4624.	3.7	22
33	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 164.	6.2	29
34	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	12.8	17
35	The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5584-5587.	5.2	8
36	Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. <i>Trials</i> , 2021, 22, 765.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Myelodysplastic Syndromes and Metabolism. International Journal of Molecular Sciences, 2021, 22, .	4.1	0
38	Myelodysplastic Syndromes and Metabolism. International Journal of Molecular Sciences, 2021, 22, 11250.	4.1	3
39	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. Blood, 2021, 138, 223-223.	1.4	1
40	Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro. Blood, 2021, 138, 2596-2596.	1.4	1
41	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. Frontiers in Genetics, 2021, 12, 811291.	2.3	2
42	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. Frontiers in Oncology, 2021, 11, 776946.	2.8	1
43	Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. Bone Marrow Transplantation, 2020, 55, 367-375.	2.4	10
44	Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation. Cytotherapy, 2020, 22, 21-26.	0.7	4
45	Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 691-697.	2.0	8
46	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Advances, 2020, 4, 5011-5024.	5.2	85
47	Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 Internal Tandem Duplication Mutation (SORMAIN). Journal of Clinical Oncology, 2020, 38, 2993-3002.	1.6	335
48	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. Lancet Haematology, 2020, 7, e884-e891.	4.6	38
49	Long-term in vivo imaging reveals tumor-specific dissemination and captures host tumor interaction in zebrafish xenografts. Scientific Reports, 2020, 10, 13254.	3.3	20
50	A Novel Synthetic, Xeno-Free Biomimetic Surface for Serum-Free Expansion of Human Mesenchymal Stromal Cells. Advanced Biology, 2020, 4, 2000008.	3.0	7
51	UV protection for young athletes: using participatory program planning to develop a sports schools program. Environmental Health and Preventive Medicine, 2020, 25, 39.	3.4	3
52	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa). Cancers, 2020, 12, 3590.	3.7	31
53	Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. Blood Advances, 2020, 4, 6077-6085.	5.2	40
54	EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica, 2020, 105, e228-e231.	3.5	29

#	ARTICLE	IF	CITATIONS
55	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	5.2	39
56	The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸ F-FDG-PET/CT: final results from the prospective PETAML trial. <i>Haematologica</i> , 2020, 105, 1552-1558.	3.5	31
57	Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model. <i>Nanoscale</i> , 2020, 12, 13582-13594.	5.6	13
58	Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia. <i>Biomarker Research</i> , 2020, 8, 20.	6.8	7
59	Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 1338.	4.8	60
60	Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 2173-2180.	1.8	12
61	External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. <i>Blood</i> , 2020, 135, 1386-1395.	1.4	36
62	Skeletal health in patients following allogeneic hematopoietic cell transplantation. <i>Bone</i> , 2020, , 115684.	2.9	1
63	An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	1.4	2
64	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
65	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	1.4	0
66	Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1401-1415.	4.2	27
67	T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. <i>Oncolmmunology</i> , 2019, 8, e1621676.	4.6	17
68	Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies?. <i>Haematologica</i> , 2019, 104, 1101-1102.	3.5	1
69	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	4.8	48
70	Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2823-2834.	2.5	7
71	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	2.4	41
72	Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 735-740.	2.5	13

#	ARTICLE	IF	CITATIONS
73	Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019. Multiple Sclerosis and Related Disorders, 2019, 32, 114-115.	2.0	1
74	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
75	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. Bone Marrow Transplantation, 2019, 54, 1662-1667.	2.4	22
76	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	1.6	163
77	Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. Journal of Immunology, 2019, 202, 1735-1746.	0.8	7
78	Spheroid Culture of Mesenchymal Stromal Cells Results in Morphorheological Properties Appropriate for Improved Microcirculation. Advanced Science, 2019, 6, 1802104.	11.2	31
79	A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. Blood Advances, 2019, 3, 1330-1346.	5.2	36
80	Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System. Frontiers in Immunology, 2019, 10, 38.	4.8	35
81	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e128-e140.	2.0	40
82	Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. British Journal of Haematology, 2019, 184, 833-836.	2.5	6
83	Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocrine Connections, 2019, 8, 923-934.	1.9	15
84	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. Journal of Autoimmunity, 2018, 90, 116-131.	6.5	64
85	Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematology, 2018, 5, e201-e210.	4.6	44
86	Noncovalently Assembled Electroconductive Hydrogel. ACS Applied Materials & Interfaces, 2018, 10, 14418-14425.	8.0	50
87	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematology, 2018, 5, e161-e169.	4.6	67
88	Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncology, 2018, 19, 1668-1679.	10.7	250
89	Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor. Biology of Blood and Marrow Transplantation, 2018, 24, 2171-2177.	2.0	25
90	Detection of human disease conditions by single-cell morpho-rheological phenotyping of blood. ELife, 2018, 7, .	6.0	125

#	ARTICLE	IF	CITATIONS
91	Targeting Leukemia Stem Cells in the Bone Marrow Niche. <i>Biomedicines</i> , 2018, 6, 22.	3.2	14
92	Pilot Study on Mass Spectrometryâ€‘Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. <i>Proteomes</i> , 2018, 6, 11.	3.5	10
93	Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Leukemia</i> , 2018, 32, 2020-2024.	7.2	23
94	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	1.4	19
95	Retargeting of UniCAR T cells with an <i>in vivo</i> synthesized target module directed against CD19 positive tumor cells. <i>Oncotarget</i> , 2018, 9, 7487-7500.	1.8	38
96	Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By Luspatercept. <i>Blood</i> , 2018, 132, 939-939.	1.4	0
97	PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1472-1472.	1.4	2
98	Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. <i>Scientific Reports</i> , 2017, 7, 42855.	3.3	51
99	Combined influence of biophysical and biochemical cues on maintenance and proliferation of hematopoietic stem cells. <i>Biomaterials</i> , 2017, 138, 108-117.	11.4	47
100	Enumeration of WT1â€‘specific CD8 ⁺ T cells for clinical application using an MHC <i>streptamer</i> based <i>no-wash single-platform flow-cytometric</i> assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 1001-1008.	1.5	1
101	Dynamics of epigenetic age following hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, e321-e323.	3.5	34
102	A three-dimensional <i>ex vivo</i> tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche. <i>Haematologica</i> , 2017, 102, 1215-1226.	3.5	63
103	Zebrafish In-Vivo Screening for Compounds Amplifying Hematopoietic Stem and Progenitor Cells: - Preclinical Validation in Human CD34+ Stem and Progenitor Cells. <i>Scientific Reports</i> , 2017, 7, 12084.	3.3	10
104	Bone marrow niche-mimetics modulate HSPC function via integrin signaling. <i>Scientific Reports</i> , 2017, 7, 2549.	3.3	30
105	Apoptosis in mesenchymal stromal cells induces <i>in vivo</i> recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	512
106	Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by <i>streptamer</i> technology. <i>Leukemia and Lymphoma</i> , 2017, 58, 1246-1249.	1.3	8
107	Impact of Different Exercise Programs on Severe Fatigue in Patients Undergoing Anticancer Treatmentâ€‘A Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 57-66.	1.2	31
108	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , 2017, 8, 1844.	4.8	43

#	ARTICLE	IF	CITATIONS
109	Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. <i>Journal of Clinical Investigation</i> , 2017, 127, 3624-3639.	8.2	78
110	Human Bone Marrow Stromal Cells: A Reliable, Challenging Tool for <i>In Vitro</i> Osteogenesis and Bone Tissue Engineering Approaches. <i>Stem Cells International</i> , 2016, 2016, 1-14.	2.5	19
111	Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome. <i>Stem Cells</i> , 2016, 34, 357-366.	3.2	80
112	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. <i>Stem Cells</i> , 2016, 34, 2224-2235.	3.2	13
113	A high BMI is a risk factor in younger patients with <i>de novo</i> acute myelogenous leukemia. <i>European Journal of Haematology</i> , 2016, 97, 17-24.	2.2	21
114	Mechanical phenotyping of primary human skeletal stem cells in heterogeneous populations by real-time deformability cytometry. <i>Integrative Biology (United Kingdom)</i> , 2016, 8, 616-623.	1.3	42
115	Breast cancer cells compete with hematopoietic stem and progenitor cells for intercellular adhesion molecule 1-mediated binding to the bone marrow microenvironment. <i>Carcinogenesis</i> , 2016, 37, 759-767.	2.8	22
116	In Vivo Chemical Screen in Zebrafish Embryos Identifies Regulators of Hematopoiesis Using a Semiautomated Imaging Assay. <i>Journal of Biomolecular Screening</i> , 2016, 21, 956-964.	2.6	14
117	Tunneling nanotubes mediate the transfer of stem cell marker CD133 between hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2016, 44, 1092-1112.e2.	0.4	36
118	Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2016, 44, 1024-1033.e1.	0.4	3
119	Distinguishing autocrine and paracrine signals in hematopoietic stem cell culture using a biofunctional microcavity platform. <i>Scientific Reports</i> , 2016, 6, 31951.	3.3	29
120	Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome—a pilot study. <i>Leukemia Research</i> , 2016, 47, 128-135.	0.8	11
121	Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 462-469.	2.0	74
122	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). <i>Blood</i> , 2016, 128, 2304-2304.	1.4	1
123	Implementation of Diagnostic Flow Cytometry Allows for the Dissection of Age Related Loss of Y Chromosome from Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2016, 128, 5531-5531.	1.4	0
124	Flow Cytometric Response Monitoring in MDS with Del(5q) Using a Simple 5-Parameter-Score - an Elnet lmds-Flow Experience. <i>Blood</i> , 2016, 128, 3179-3179.	1.4	0
125	RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. <i>Blood</i> , 2015, 125, 3760-3768.	1.4	53
126	Phenotypic, Morphological and Adhesive Differences of Human Hematopoietic Progenitor Cells Cultured on Murine versus Human Mesenchymal Stromal Cells. <i>Scientific Reports</i> , 2015, 5, 15680.	3.3	14

#	ARTICLE	IF	CITATIONS
127	Preventive brain radiochemotherapy alters plasticity associated metabolite profile in the hippocampus but seems to not affect spatial memory in young leukemia patients. <i>Brain and Behavior</i> , 2015, 5, e00368.	2.2	3
128	Reduced-Intensity Conditioning Combined with ¹⁸⁸ Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1754-1760.	2.0	12
129	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. <i>Cytotherapy</i> , 2015, 17, 473-486.	0.7	149
130	Allogeneic Stem-Cell Transplantation in Patients With <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-410.	1.6	74
131	Vosaroxin in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2015, 16, 1000-1001.	10.7	4
132	Extracellular matrix deposition of bone marrow stroma enhanced by macromolecular crowding. <i>Biomaterials</i> , 2015, 73, 60-69.	11.4	69
133	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	10.7	347
134	Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. <i>Onc Immunology</i> , 2015, 4, e1008342.	4.6	19
135	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. <i>International Journal of Cancer</i> , 2015, 136, 44-54.	5.1	35
136	Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 35095-35106.	1.8	12
137	Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 38804-38815.	1.8	14
138	Concise Review: The Bone Marrow Niche as a Target of Graft Versus Host Disease. <i>Stem Cells</i> , 2014, 32, 1420-1428.	3.2	22
139	Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis. <i>Annals of Hematology</i> , 2014, 93, 279-285.	1.8	21
140	Kit Regulates HSC Engraftment across the Human-Mouse Species Barrier. <i>Cell Stem Cell</i> , 2014, 15, 227-238.	11.1	142
141	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
142	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 279-281.	2.0	83
143	Outcome of patients with <i>abn(17p)</i> acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	1.4	62
144	Clonal Hematopoiesis in AML Patients in Hematological CR Is Present in Many Patients with Intermediate Risk AML and Is Associated with a High Prevalence of DNMT3A gene Mutations. <i>Blood</i> , 2014, 124, 121-121.	1.4	9

#	ARTICLE	IF	CITATIONS
145	Flexible Antigen-Specific Redirection of Human Regulatory T Cells Via a Novel Universal Chimeric Antigen Receptor System. <i>Blood</i> , 2014, 124, 3494-3494.	1.4	41
146	Interaction of Tumor Cells with the Hematopoietic Stem and Progenitor Cell Niche. <i>Blood</i> , 2014, 124, 5139-5139.	1.4	3
147	A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells. <i>PLoS ONE</i> , 2014, 9, e93745.	2.5	37
148	Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2014, 124, 4626-4626.	1.4	0
149	Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease. <i>Blood</i> , 2014, 124, 2384-2384.	1.4	0
150	CD97 Expression in Acute Myeloid Leukemia Is Associated with FLT3-ITD Mutation Status. <i>Blood</i> , 2014, 124, 1001-1001.	1.4	0
151	Allogeneic Stem Cell Transplantation after Conditioning with Treosulfan, Etoposide and Cyclophosphamide for Patients with Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-Containing Regimens: A Phase II-Study on Behalf of the German ALL Study Group (GMALL) and the German Cooperative Transplant Study Group. <i>Blood</i> , 2014, 124, 2461-2461.	1.4	0
152	Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. <i>Experimental Hematology</i> , 2013, 41, 444-461.e4.	0.4	25
153	Overexpression of Jagged-1 and Its Intracellular Domain in Human Mesenchymal Stromal Cells Differentially Affect the Interaction with Hematopoietic Stem and Progenitor Cells. <i>Stem Cells and Development</i> , 2013, 22, 2736-2750.	2.1	13
154	Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. <i>Nature Methods</i> , 2013, 10, 788-794.	19.0	195
155	High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2102.	1.6	71
156	TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. <i>Oncolmmunology</i> , 2013, 2, e26770.	4.6	8
157	Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. <i>Haematologica</i> , 2013, 98, 505-513.	3.5	32
158	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. <i>Blood</i> , 2013, 122, 489-489.	1.4	1
159	Enhancing The Efficacy and Specificity Of Antibody-Based T Cell Retargeting Strategies Against Hematological Malignancies. <i>Blood</i> , 2013, 122, 930-930.	1.4	4
160	Factors Influencing Peripheral Blood Progenitor Cell Yield After 2nd Mobilization With G-CSF In Allogeneic Donors. <i>Blood</i> , 2013, 122, 3274-3274.	1.4	0
161	Response and Long-Term Outcome After Treatment With Third-Party Mesenchymal Stromal Cells - Updated Results In 58 Patients With Steroid-Refractory Acute Graft-Versus Host Disease -. <i>Blood</i> , 2013, 122, 4612-4612.	1.4	1
162	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 711-711.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Screening For Anti-Leukemic CTLs After Allogeneic Hematopoietic Stem Cell Transplantation Applying Streptamer Technology. <i>Blood</i> , 2013, 122, 5493-5493.	1.4	0
164	Influence Of Steroid Exposure On CMV Specific T Cells Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5488-5488.	1.4	0
165	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial –. <i>Blood</i> , 2013, 122, 304-304.	1.4	0
166	Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.4	0
167	Azacitidine and Donor Lymphocyte Infusions As Treatment For Relapse After Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis In 115 Patients On Behalf Of The German Cooperative Transplant Study Group. <i>Blood</i> , 2013, 122, 4642-4642.	1.4	0
168	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. <i>Experimental Hematology</i> , 2012, 40, 934-944.	0.4	19
169	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	27.6	352
170	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1035-1044.	10.7	237
171	OXPPOS Supercomplexes as a Hallmark of the Mitochondrial Phenotype of Adipogenic Differentiated Human MSCs. <i>PLoS ONE</i> , 2012, 7, e35160.	2.5	83
172	On the symmetry of siblings: automated single-cell tracking to quantify the behavior of hematopoietic stem cells in a biomimetic setup. <i>Experimental Hematology</i> , 2012, 40, 119-130.e9.	0.4	36
173	KIR Haplotype B Donors but Not KIR-Ligand Mismatch Result in a Reduced Risk of Relapse After Haploidentical Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning and a CD3/CD19 Depleted Graft.. <i>Blood</i> , 2012, 120, 3101-3101.	1.4	0
174	Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 7174-7184.	1.4	48
175	Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module. <i>Molecular Immunology</i> , 2011, 49, 474-482.	2.2	40
176	Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2011, 5, 648-654.	2.7	47
177	Cytarabine Dose of 36 g/m ² Compared With 12 g/m ² Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2696-2702.	1.6	94
178	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , 2011, 118, 157-157.	1.4	1
179	Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients. <i>Blood</i> , 2011, 118, 489-489.	1.4	1
180	A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial. <i>Blood</i> , 2011, 118, 497-497.	1.4	4

#	ARTICLE	IF	CITATIONS
181	A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> , 2010, 116, 971-978.	1.4	157
182	Impact of CXCR4 inhibition on FLT3-ITD ⁺ positive human AML blasts. <i>Experimental Hematology</i> , 2010, 38, 180-190.	0.4	36
183	¹⁸⁸ <i>Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. British Journal of Haematology</i> , 2010, 148, 910-917.	2.5	21
184	Polarization and Migration of Hematopoietic Stem and Progenitor Cells Rely on the RhoA/ROCK I Pathway and an Active Reorganization of the Microtubule Network. <i>Journal of Biological Chemistry</i> , 2010, 285, 31661-31671.	3.4	51
185	Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro. <i>Haematologica</i> , 2010, 95, 542-550.	3.5	190
186	Cancellous bone allograft seeded with human mesenchymal stromal cells: a potential good manufacturing practice-grade tool for the regeneration of bone defects. <i>Cytotherapy</i> , 2010, 12, 658-668.	0.7	17
187	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. <i>Blood</i> , 2010, 116, 680-680.	1.4	0
188	Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. <i>Experimental Hematology</i> , 2009, 37, 504-513.	0.4	80
189	Endogenous bone morphogenetic proteins in human bone marrow-derived multipotent mesenchymal stromal cells. <i>European Journal of Cell Biology</i> , 2009, 88, 257-271.	3.6	46
190	Biological activity of extracellular matrix-associated BMP-2. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2009, 4, 324-327.	2.7	13
191	The growth and differentiation of mesenchymal stem and progenitor cells cultured on aligned collagen matrices. <i>Biomaterials</i> , 2009, 30, 5950-5958.	11.4	118
192	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	10.7	620
193	Engineered Extracellular Matrices Modulate the Expression Profile and Feeder Properties of Bone Marrow-Derived Human Multipotent Mesenchymal Stromal Cells. <i>Tissue Engineering - Part A</i> , 2009, 15, 3161-3171.	3.1	26
194	Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1613-1617.	3.5	98
195	Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution. <i>Blood</i> , 2009, 114, 1203-1203.	1.4	0
196	Oxygen Tension Regulates Hematopoietic Stem Cell Migration Into An in-Vitro Niche Beneath Mesenchymal Stromal Cells. <i>Blood</i> , 2009, 114, 1443-1443.	1.4	0
197	Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 5585-5593.	7.0	26
198	Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party. <i>Journal of Clinical Oncology</i> , 2007, 25, 4938-4945.	1.6	446

#	ARTICLE	IF	CITATIONS
199	Polarization of Human Hematopoietic Progenitors During Contact with Multipotent Mesenchymal Stromal Cells: Effects on Proliferation and Clonogenicity. <i>Stem Cells and Development</i> , 2006, 15, 815-829.	2.1	66
200	Gene-Expression Profiling of CD34+Hematopoietic Cells Expanded in a Collagen I Matrix. <i>Stem Cells</i> , 2006, 24, 494-500.	3.2	78
201	Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. <i>European Journal of Haematology</i> , 2006, 76, 9-17.	2.2	43
202	Highly Sensitive Real-Time PCR of V617F-JAK2-Mutation To Monitor Minimal Residual Disease and Guide Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.. <i>Blood</i> , 2006, 108, 669-669.	1.4	7
203	A second infusion of CD34+ selected cells to improve poor graft function. <i>Haematologica</i> , 2006, 91, 870.	3.5	1
204	Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Blood</i> , 2005, 106, 3314-3321.	1.4	67
205	Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro. <i>Stem Cells</i> , 2004, 22, 377-384.	3.2	1,143
206	Successful combination of anti-cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 1093-1094.	2.5	4
207	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. <i>Blood</i> , 2002, 99, 4326-4335.	1.4	1,550
208	CD34+ -enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. <i>British Journal of Haematology</i> , 2002, 118, 1095-1103.	2.5	24
209	Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. <i>Annals of Hematology</i> , 2001, 80, 144-149.	1.8	20
210	Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. <i>British Journal of Haematology</i> , 2001, 115, 119-124.	2.5	38